Galectin Therapeutics Inc. filings document a clinical-stage biotechnology issuer developing galectin-targeted therapeutics, including belapectin for MASH cirrhosis and portal hypertension. Form 8-K reports furnish operating results, financial condition updates, business updates, Regulation FD materials, and clinical-program disclosures tied to NAVIGATE trial presentations and corporate presentations.
The company’s proxy and governance filings cover director elections, advisory votes on executive compensation, auditor ratification, board changes, officer compensation arrangements, and annual meeting results. Its SEC records also identify GALT common stock registered on The Nasdaq Stock Market and include risk-factor references related to forward-looking clinical development and financing needs.
Galectin Therapeutics Inc. (GALT) is asking stockholders to elect 11 directors and vote on three other proposals at its virtual annual meeting on December 3, 2026: increasing authorized common stock from 150,000,000 to 250,000,000 shares, reserving an additional 3,000,000 shares under its 2019 Omnibus Equity Incentive Plan, and ratifying Cherry Bekaert LLP as auditor for 2026. Common and Series A preferred holders of record on October 6, 2026 may vote.
On July 31, 2026, Richard E. Uihlein, the company’s chairman and largest stockholder, converted all outstanding convertible notes from prior credit facilities. The conversion eliminated $91.0 million in principal and approximately $14.8 million in accrued interest—approximately $105.8 million total—in exchange for 34,376,167 common shares at a blended average conversion price of approximately $3.07 per share. The shares remain subject to resale restrictions; Galectin must file a resale registration statement within 180 days after Uihlein’s written request and use commercially reasonable efforts to make it effective as promptly as practicable thereafter.
Galectin Therapeutics (GALT) is asking stockholders at its December 3, 2026 virtual annual meeting to elect 11 directors, approve a proposed amendment increasing authorized common shares from 150,000,000 to 250,000,000, reserve an additional 3,000,000 shares under its 2019 Omnibus Equity Incentive Plan, and ratify Cherry Bekaert LLP for fiscal 2026. Holders of common stock or Series A 12% convertible preferred stock as of October 6, 2026, may vote.
On July 31, 2026, Chairman and largest stockholder Richard E. Uihlein converted outstanding notes, eliminating $91.0 million in aggregate principal and approximately $14.8 million in accrued interest—approximately $105.8 million total—in exchange for 34,376,167 common shares. The conversion was subject to a $3.00-per-share floor and resulted in a blended average conversion price of approximately $3.07 per share. A separate December 2025 credit line of up to $10.0 million remained outstanding, undrawn and available as of the proxy statement date.
Galectin Therapeutics Inc. reported a larger net loss for the three months ended June 30, 2026 while advancing its lead drug belapectin toward a registrational Phase 3 trial in MASH cirrhosis and portal hypertension. Net loss was $9.1 million versus $7.5 million a year earlier, with total operating expenses of $4.0 million, down from $4.6 million, reflecting lower research and development spending partly offset by higher general and administrative expenses.
Cash and cash equivalents were $13.3 million and total liabilities $151.7 million as of June 30, 2026, resulting in a stockholders’ deficit of $(138.6) million. Management highlighted an agreement with the FDA on key elements of the planned registrational Phase 3 belapectin trial and noted the recent issuance of common stock converting approximately $105.8 million of debt and accrued interest owed to the company’s chairman, which it stated significantly enhanced the capital structure.
Galectin Therapeutics Inc. reports it remains a clinical-stage company with no revenue and continuing losses. For the six months ended June 30, 2026, net loss was $14,159 (in thousands), improving from $17,152 (in thousands) in 2025, as research and development expenses fell to $4,366 (in thousands) from $9,746 (in thousands).
Cash and cash equivalents were $13,269 (in thousands), and management expects existing cash plus a related-party credit line to fund operations through June 2027. However, substantial doubt is raised about the ability to continue as a going concern beyond 12 months from issuance without additional capital. The balance sheet shows a significant stockholders’ deficit of $138,575 (in thousands) and large related-party convertible debt and derivative liabilities.
The company discloses detailed terms of multiple convertible notes and credit facilities from its chairman and significant fair value increases in related derivative liabilities. A subsequent event on July 31, 2026 converted $91,000,000 of principal and $14,806,981 of accrued interest under these facilities into 34,376,167 common shares, extinguishing that debt. Galectin also discusses NAVIGATE Phase 2b/3 trial results for belapectin in MASH cirrhosis, noting mixed primary outcomes but favorable per-protocol and U.S. subgroup data, alongside a continued focus on partnering and future oncology development subject to financing.
Richard E. Uihlein reports beneficial ownership of 54,673,646.00 shares of Galectin Therapeutics Inc. common stock, representing approximately 49.30% of the outstanding class. He has sole voting and sole dispositive power over these shares, which are held for investment purposes rather than to change or influence control.
The stake consists of 44,736,553 shares of common stock and 9,937,093 shares issuable upon conversion of warrants, options and other convertible securities. On July 31, 2026, he converted debt of approximately $105.8, consisting of $91.0 million of principal and approximately $14.8 million of accrued interest, into 34,376,167 shares of common stock. His investment is described as funded with personal funds.
Galectin Therapeutics director and over-10% holder Richard E. Uihlein, via the Richard E. Uihlein Stock Trust, exercised Line of Credit Convertible Notes into 31,825,235 and 2,550,932 common shares at $3.00 and $4.05 per share. The notes totaled $91,000,000 and $10,000,000 of principal plus accrued interest. A holding entry reports 27,710 shares held by the Ed Uihlein Family Foundation, where Uihlein shares voting power but has no pecuniary interest.
Galectin Therapeutics Inc. converted approximately $105.8 million of debt owed to its chairman and largest stockholder, Richard E. Uihlein, into equity effective July 31, 2026. The conversion eliminated $91.0 million of principal and about $14.8 million of accrued interest arising from five line-of-credit facilities.
In exchange, the company issued 34,376,167 shares of common stock at a blended average conversion price of about $3.07 per share, using the Section 3(a)(9) exemption from registration. After the transaction, 100,849,644 common shares and 197,500 Series A Voting Preferred shares were outstanding, and Mr. Uihlein beneficially holds roughly 44.3% of voting power, or 49.3% including warrants. A separate $10 million supplemental credit facility from December 2025 remains undrawn and available, and the company is obligated to register the resale of the new shares within 180 days of conversion.
Galectin Therapeutics Chief Medical Officer Jamil Khurram exercised stock options to acquire 16,250 common shares at $3.04 per share and sold 16,250 shares at a weighted average price of $5.1252 on July 14, 2026, under a Rule 10b5-1 trading plan. Following the derivative transaction, he held 48,750 stock options.
Galectin Therapeutics director Harold H. Shlevin reported option exercises paired with share sales in Galectin Therapeutics Inc. common stock. On June 26 and June 29, 2026, he exercised stock options to acquire a total of 30,000 shares at an exercise price of $1.23 per share and sold 30,000 shares in open-market transactions.
Sales on June 26 covered 7,732 shares at $5.00 per share, while June 29 sales covered 22,268 shares at a weighted average price of $5.04, with individual trades ranging from $5.00 to $5.12. The filing notes these transactions were executed under a Rule 10b5-1 trading plan adopted on August 29, 2025. After these trades, Shlevin directly holds 6,500 shares of Galectin common stock, and the exercised options had fully vested on December 31, 2025.